Pacylex Presents Updates on the Journey of PCLX-001 to the Clinic at BIO and FASEB Conferences

On the heels of closing its Series A last month, Pacylex CEO Michael Weickert will present at The Biotechnology Innovation Organization (BIO) Digital 2021 International Convention as part of the Alberta Life Sciences Showcase event on Tuesday, June 15 at 3:00 – 5:30 PM (UTC-07:00) Mountain Time (US & Canada). This update will include progress towards the initiation of the first clinical trial with PCLX-001 in the next month.

Later this month, Dr. Luc Berthiaume, CSO of Pacylex, will present an overview of the journey of discovery to clinical trials in cancer patients of the NMT inhibitor, PCLX-001, at the FASEB (Federation of American Societies for Experimental Biology) Scientific Research Conference: The Protein Lipidation Conference: Enzymology, Signaling and Therapeutics.

FASEB Presentation Details:

Title of talk: “N-myristoyltransferase inhibitors for lymphoma and leukemia: our journey to clinical trials"

Date: June 30, 2021

Time: 10:55 am - 11:15 am EDT

June 15, 2021